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Introduction {#sec001}
============

Arthropod-borne diseases are one of the most important health problems in the world. Today, more than one-third of infections are caused by communicable diseases by vectors. Leishmaniasis is a vector-borne disease transferred by more than 20 types of *Leishmania* parasites belonging to the *Kinetoplastida* class and the family *Trypanosomatidae* \[[@pone.0236414.ref001], [@pone.0236414.ref002]\]. Leishmaniasis has been reported in more than 101 countries \[[@pone.0236414.ref003]\], and over 350 million people face the grave risk of the disease \[[@pone.0236414.ref004]\]. The most important vectors of the leishmaniasis in the old world are sandflies of the genus *Phlebotomus* and *Lutzomyia* in the new world \[[@pone.0236414.ref005]\]. In terms of clinical symptoms, leishmaniasis is classified into the following varieties: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL) and mucocutaneous leishmaniasis (MCL) \[[@pone.0236414.ref006], [@pone.0236414.ref007]\]. VL, also known as kala-azar, is an intense, hard form of leishmaniasis \[[@pone.0236414.ref008]\]. It is estimated to have caused 0.2--0.4 million cases worldwide resulting in over 40,000 deaths annually \[[@pone.0236414.ref009], [@pone.0236414.ref010]\].

VL in Iran is of the Mediterranean type and is caused by *Leishmania infantum* \[[@pone.0236414.ref007], [@pone.0236414.ref011]\]. Dogs and canines \[[@pone.0236414.ref012], [@pone.0236414.ref013]\] have been introduced as the main reservoirs, and 100--300 endemic and sporadic human cases annually occur in different regions in Iran \[[@pone.0236414.ref014]\]. After the observance of the first case of VL in Iran in 1949, at least four main foci of the disease have been investigated thus far in some parts of Ardabil, Fars, East Azerbaijan and Bushehr provinces where the most important focus of the disease has been reported to be the northwestern region of Iran (Ardabil and East Azerbaijan) \[[@pone.0236414.ref014], [@pone.0236414.ref015]\]. In Iran, infections occur more in children, and more than 89% of the patients in endemic areas are children under the age of five years \[[@pone.0236414.ref016]\]. The most important symptoms of VL include fever, hepatosplenomegaly, and anemia \[[@pone.0236414.ref017], [@pone.0236414.ref018]\]. Currently, 25--50% of VL cases occur in the northwest of Iran and hence it is one of the most important centers of the disease in the country \[[@pone.0236414.ref019], [@pone.0236414.ref020]\].

The use of Geographic Information System (GIS) is a new approach in the study of vector*-*borne diseases (VBDs), such as VL, and has led to significant changes in data interpretation and decision making \[[@pone.0236414.ref021]\]. Using geographic technology, researchers now have the opportunity to get informed about the distribution of the disease and its extent, identify and control the high-risk areas of the disease and take the necessary environmental interventions. Accordingly, there is a high correlation between the occurrence of the VL disease and the environmental factors involved in it in terms of geographical distribution and their relationship with the disease \[[@pone.0236414.ref022]\]. In an 18-year study that examined the status of VL in Italy based on GIS and the MaxEnt software, the overall increase in the disease was found to be related to the level of the patients' immune system and the impact of the social status of the endemic region on individuals where the disease was sporadic \[[@pone.0236414.ref023]\]. To understand and predict where the outbreak of diseases can happen, the ecological niche models and drawings of different maps can be used with the MaxEnt and GIS software, respectively \[[@pone.0236414.ref024]\]. Ecological niche modeling is also used to understand the probability of the presence of a disease in a specific location \[[@pone.0236414.ref025]\]. In fact, these models help find answers to ecological questions and identify the distribution of diseases that can be potentially epidemic disease \[[@pone.0236414.ref026]\].

Accordingly, this study aimed to investigate the geographical distribution of VL in three provinces of Ardabil, East Azerbaijan and West Azerbaijan (northwestern Iran) and determine the high-risk areas of the disease in the provinces and its relation with environmental and geographical factors. Another objective of the study was to determine the environmental suitability for VL in northwestern Iran for prevention and control of diseases.

Material and methods {#sec002}
====================

Study area {#sec003}
----------

Azerbaijan is located in the northwest of Iran, at the intersection of Alborz, Zagros and Caucasus Mountains and is a mainly mountainous region consisting of Ardabil, East Azerbaijan and West Azerbaijan provinces. This area is between 34.550--38.4853° N and 45.0001--48. 911°E ([Fig 1](#pone.0236414.g001){ref-type="fig"}). In most parts of the west and northwest of Azerbaijan, the weather is Mediterranean humid and in the southern region, it is Mediterranean with hot summers. Due to the European route, this region has obtained a special position. It borders the Republic of Azerbaijan, Armenia, and Turkey. According to the latest census in 2016, the population of the Azerbaijan region is 10.56% (8,445,291) of the total population of Iran.

![](pone.0236414.g001){#pone.0236414.g001}

The ethics committee waived the need of consent from patients {#sec004}
-------------------------------------------------------------

### The implementation of the study {#sec005}

In this retrospective cross-sectional study, the Data on VL cases were collected from Ardabil, East Azerbaijan and West Azerbaijan Provinces health centers during the last 9yr from January 2009 to the end of December 2017. The number of patients with Direct Agglutination Test (DAT) positive serologic tests was more than 1:3200 cases with medical records, diagnosed by physicians and treated in different parts of the province. By referring to health centers in different counties and reviewing patients' hospital and health records, demographic characteristics, including age, sex, place of residence, month and year of the disease as well as the results of the DAT test were collected. Then, the data collected were compared with the general statistics in the offices of the vice-chancellor for the health of the provinces of East Azerbaijan, West Azerbaijan, and Ardabil, and the results of the comparison were recorded. The collected data were stored in an ArcMap environment based on the patients' addresses.

Ethical grant was approved by Ardabil University of Medical Sciences by the following number: IR-ARUMS.REC.1397.112.

Data analysis {#sec006}
-------------

The effect of variables, such as age, sex and location, on the prevalence (No. of VL cases/population size ~\*~ 100000) of the disease was evaluated using SPSS version 23(Chicago, IL, USA), and T-test and Kruskal-Wallis statistical tests were run at a 95% confidence level. In order to perform the spatial analysis, the data were entered into the spatial data bank in the ArcGIS10.4.1 software, and the distribution maps of the disease cases in different years were drawn in the ArcMap environment. Spatial autocorrelations and determination of high/low clustering of VL cases in different counties of the study area were estimated. The spatial autocorrelation tool in ArcGIS measures spatial autocorrelation based on both features of locations and values simultaneously. Given the VL cases data and the associated attribute (district border), the pattern of the disease (clustered, dispersed or random) was evaluated. Moran\'s I Index and General G value were measured, and both the score and p-values (p \< 0.05) were calculated and used to evaluate the significance of the index \[[@pone.0236414.ref027]\]. Moran's I is a commonly used indicator of spatial autocorrelation. In this study, global Moran's I was used as the first measure of spatial autocorrelation. Its values range from−1 to 1. The value "1" means perfect positive spatial autocorrelation (high values or low values cluster together), while "−1" suggests perfect negative spatial auto-correlation (a checkerboard pattern), and "0" implies perfect spatial randomness \[[@pone.0236414.ref028], [@pone.0236414.ref029]\]. The High/Low Clustering (General G) tool measures how concentrated the high or low values are for a given study area. This tool calculates the High/Low General G value (observed & expected) & the associated Z score & p-value for a given input feature class \[[@pone.0236414.ref030]\].

Thus, the index was measured by the following formulas: $$G = \frac{{\sum_{i}^{N}{= 1\ {\sum_{j}^{N}{= 1}}}}Wij\ xi\ xj}{\sum_{i}^{N}{= 1\ {\sum_{j}^{N}{= 1\ xi\ xj}}}},j \neq i\mspace{54mu} I = \frac{N}{W}\frac{\sum{i\ {\sum{j\ \omega ij\left( {xi - x} \right)\left( xj - x \right)}}}}{\sum{i\ \left( xi - x \right)}}$$

Modeling {#sec007}
--------

To model the ecological niches of the parasite *L*. *infantum*, the coordinates of 42 points from different regions of Azerbaijan where more than two cases were reported in 2009--2017 were entered into the Excel environment and stored in the CSV format. Then, they were evaluated using the MaxEnt3.3 software \[[@pone.0236414.ref031]\]. A total of 19 climate variables were downloaded from the Worldclime website ([www.worldclime.com](http://www.worldclime.com/)) with a resolution of 30 sec (≌1 sq.km) and were used along with an elevation variable at the same resolution to evaluate and determine the appropriate ecological niches ([Table 1](#pone.0236414.t001){ref-type="table"}). The Jackknife analysis was employed to find the most important variable in the model. Jackknife test was used to analyse the relationship between weather variables and distribution of *L*.*infantum* and the relevant variables were identified with percentages and non-relevant variables were assigned zero.

10.1371/journal.pone.0236414.t001

###### Variables used for MaxEnt modeling of VL distribution in Ardabil, East Azerbaijan and West Azerbaijan, Northwest of Iran.
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  Variable       Description                                                     Contribution (%)
  -------------- --------------------------------------------------------------- ------------------
  **Bio1**       Annual mean temperature (^o^C)                                  0
  **Bio2**       Mean diurnal range: mean of monthly (max temp--min temp) (°C)   21.6
  **Bio3**       Isothermality: (Bio2/Bio7) × 100                                5.5
  **Bio4**       Temperature seasonality (SD × 100)                              5.9
  **Bio5**       Maximum temperature of warmest month (°C)                       7.7
  **Bio6**       Minimum temperature of coldest month (°C)                       3.4
  **Bio7**       Temperature annual range (Bio5 − Bio6) (°C)                     0.1
  **Bio8**       Mean temperature of wettest quarter (°C)                        0.1
  **Bio9**       Mean temperature of driest quarter (°C)                         0
  **Bio10**      Mean temperature of warmest quarter (°C)                        0
  **Bio11**      Mean temperature of coldest quarter (°C)                        9
  **Bio12**      Annual precipitation (mm)                                       0.1
  **Bio13**      Precipitation of wettest month (mm)                             4.5
  **Bio14**      Precipitation of driest month (mm)                              0
  **Bio15**      Precipitation seasonality (coefficient of variation)            35.4
  **Bio16**      Precipitation of wettest quarter (mm)                           0.1
  **Bio17**      Precipitation of driest quarter (mm)                            3.8
  **Bio18**      Precipitation of warmest quarter (mm)                           0.2
  **Bio19**      Precipitation of coldest quarter (mm)                           2.1
  **Altitude**   Elevation from the sea level (m)                                0.7

Results {#sec008}
=======

Demography and the disease distribution {#sec009}
---------------------------------------

Over the 9-year period of the study, there were 202 cases with a positive result of VL disease throughout the northwest region of Iran, with the highest incidence in Ardabil Province (51%), and East Azerbaijan Province (47.50%) and the lowest in West Azerbaijan Province (1.50%). VL was distributed in 22 counties from all three provinces so that more than three cases were reported in 15 counties, most of them located in the western parts of Azerbaijan. Germi (17.80%), Ahar (14.90%), Meshkin Shahr (14.40%) and Kaleybar 10.40%) had the highest number of VL cases ([Fig 2](#pone.0236414.g002){ref-type="fig"}). This disease was reported from 119 areas in the Azerbaijan region of which 83% were rural areas and 17% were urban areas ([Fig 3](#pone.0236414.g003){ref-type="fig"}).

![](pone.0236414.g002){#pone.0236414.g002}

![](pone.0236414.g003){#pone.0236414.g003}

The monthly incidence of VL in the province showed that the highest infection rate was reported in March and February and the lowest in July and August. In other words, the seasonal occurrence of the disease occurred in winter (37.60%) and spring (30.70%) with a slight occurrence in summer (13.50%) ([Fig 4](#pone.0236414.g004){ref-type="fig"}). The highest number of VL cases recorded was 39 in 2009 and the fewest number of cases was eight in 2013. A total of 56% of patients were male and 44% were female. In terms of the age group, 98% of patients were under the age of 10 years, of which 68% were under two years of age and 32% were 2--10 years old; there was a statistically significant relationship between the ages of patients (p **\<** 0.05). The relationship between the incidence rate of VL and the altitude showed that more than 60% of diseases occurred at altitudes of 1000 to 1500 m, and the results of the t-test revealed that this relationship was significant (p = 0.005). Besides, the results of the Kruskal-Wallis test showed that the incidence of VL was very high in 1150--1300 m altitude (p = 0.017) ([Table 2](#pone.0236414.t002){ref-type="table"}).

![](pone.0236414.g004){#pone.0236414.g004}

10.1371/journal.pone.0236414.t002

###### The results of T-test and Kruskal--walls test for incidence of VL in Ardabil, East Azerbaijan and West Azerbaijan, Northwest of Iran, 2009--2017.
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  T-test analysis         Kruskal--walls test analysis                                                        
  ----------------------- ------------------------------ -------- ------------ ------------ -------- -------- -------
  **1000--1150**          1276                           134.21   0.005        1000--1150   371.25   532.34   0.017
  **\<1000 and \>1150**   867                            618.65   1150--1300   510.00       552.63            
                                                                               \>1300       107.33   217.95   

Spatial autocorrelation of VL in study area {#sec010}
-------------------------------------------

The results of the Moran\'s Index and General G analysis indicated that the hot spot of the disease was located in the northeastern regions of Azerbaijan (Germi, Ahar, Meshkin Shahr and Kaleybar). Given the z-score of 5.6859, there is a less than 5% likelihood that this clustered pattern could be the result of random chance (p = 0.000). The high-low clustering report of General G factor given the z-score of 5.04132446743 showed that there is a less than 1% likelihood that this high-clustered pattern could be the result of random chance (p = 0.000). These infected areas share borders with the Republic of Azerbaijan; as a result, the risk of transmission of the disease in these areas is high (Figs [5](#pone.0236414.g005){ref-type="fig"}--[7](#pone.0236414.g007){ref-type="fig"}) ([Table 3](#pone.0236414.t003){ref-type="table"}).
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10.1371/journal.pone.0236414.t003

###### The results of hot-spot and autocorrelation analysis of VL in Ardabil, East Azerbaijan and West Azerbaijan, Northwest of Iran.
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  General G Summary         Global Moran\'s I Summary                         
  ------------------------- --------------------------- --------------------- -----------
  **Observed General G:**   0.000004                    **Moran\'s Index:**   0.421890
  **Expected General G:**   0.000001                    **Expected Index:**   -0.010101
  **Variance:**             0.000000                    **Variance:**         0.005772
  **z-score:**              5.041324                    **z-score:**          5.685973
  **p-value:**              0.000000                    **p-value:**          0.000000

Modeling the ecologically suitable areas of VL {#sec011}
----------------------------------------------

Based on the findings of this study, the northeastern parts of the Azerbaijan region on the common border between Iran and the Republic of Azerbaijan, including the counties of Germi, Meshkin Shahr, Ahar and Kaleybar, are among the high-risk areas for the transmission of disease and a suitable place for the growth of *L*. *infantum* parasite ([Fig 6](#pone.0236414.g006){ref-type="fig"}). The most important climate variables affecting the distribution of VL and *L*. *infantum* parasite in the Azerbaijan region were seasonal rainfall, average daily temperature range, the average temperature in cold seasons and maximum temperature in warm months. Once, the impact of each variable on the model was evaluated separately ([Fig 8](#pone.0236414.g008){ref-type="fig"}). In addition, the impact of all variables together on the model were precipitated again. The model showed that two factors; seasonality (35.40%) and mean diurnal range (21.60%) had the greatest impact on the occurrence of the disease ([Table 1](#pone.0236414.t001){ref-type="table"}).

![](pone.0236414.g008){#pone.0236414.g008}

Discussion {#sec012}
==========

The investigation of the distribution of VL disease in the northwestern region of Iran in 2009--2017 indicated a large spread of the disease and an increase in the contaminated areas wherein nearly one-quarter of the region was infected. Throughout this 9-year period, 202 cases of the disease were identified and reported in the northwestern region of Iran. According to a previous study conducted in Iran in 1988, 5,244 cases of VL were detected of which 2,280 cases were observed in Ardabil Province, 2,020 cases in Fars Province and 175 cases in East Azerbaijan Province \[[@pone.0236414.ref032], [@pone.0236414.ref033]\]. More than 2,000 cases were diagnosed in 31 provinces of Iran in 2012 of which 44.60% were reported in the northwest of Iran \[[@pone.0236414.ref014]\], indicating that the northwestern region of Iran is one of the most important endemic foci of VL in Iran.

The results of this study demonstrated that the disease has decreased in the northwest of Iran, but has been reported in more areas and parts than before. In another study carried out in 1996, three regions, Meshkin Shahr, Moghan and Ahar, were among the areas where the disease was reported \[[@pone.0236414.ref034]\]. According to the results of this study, the disease cases were reported in 15 counties in the northwest so that the disease cases in seven counties were between 10 and 36, indicating that the distribution of the disease and the contaminated areas have generally increased. A study conducted before 2000 showed that many VL cases were reported from the three counties of Meshkin Shahr, Moghan and Ahar \[[@pone.0236414.ref026]\].

As observed in the study conducted by Marco in Brazil, the distribution of the disease and the number of contaminated areas have increased in different parts of the world. According to the findings of this study in Brazil, the incidence of VL reduced from 1999 to 2008, but its incidence spread to the various reservoirs and areas \[[@pone.0236414.ref035]\]. In India, the cases of VL dropped from around 76,500 cases in 1992 to around 12,000 cases in 2012, but the distribution of the disease increased in different states \[[@pone.0236414.ref036], [@pone.0236414.ref037]\]. Only in Afghanistan, the incidence of VL increased from 10,944 in 2003 to 32,145 cases in 2010; one of the main causes of this increase is the war in the country that has increased the number of diseases and areas of distribution \[[@pone.0236414.ref038]\].

The results of the study regarding patients\' age indicated that 98% of patients were under the age of 10 and only 2% were above 10 years old. Due to the fact that VL in Iran is of Mediterranean type and its factor is *L*. *infantum* \[[@pone.0236414.ref039]\], as far as the age is concerned, this disease occurred at an early age, while previous research in Ardabil Province had shown that 17% of cases were under two years of age \[[@pone.0236414.ref040]\], now reaching 68%. In a study conducted in Ardabil Province in 2014 \[[@pone.0236414.ref016]\], 66% of cases in Ardabil Province were under two years old, while in 2017, this rate reached 70% \[[@pone.0236414.ref041]\].

In terms of gender, most cases were male (56%) (*p* \< 0.05) indicating males are more likely to be infected. One of the reasons for such an observation can be the type of coverage for boys compared to girls. In other studies, in Pakistan and Brazil, the male/female sex ratio was 2/1, and the male patients were more than women \[[@pone.0236414.ref042]--[@pone.0236414.ref045]\].

More than 68% of cases occurred in winter and spring, and the incidence was low in summer and autumn. In terms of yearly incidence, the incidence of the disease declined by 2013, but from 2014 onward, there was a rising trend and according to the pattern of infectious diseases, it had a sine wave. In other areas of the world, including India, the cases of the disease have shown a sinusoidal pattern once every two or three years \[[@pone.0236414.ref036], [@pone.0236414.ref046]\]. The results of the analysis of Moran^\'^s Index showed that the two counties of Germi and Meshkin Shahr in Ardabil Province and the two counties of Ahar and Kaleybar in East Azarbaijan Province had the highest risk of VL infection. These areas are among the high-risk areas with high transmission risk of infection in northwestern Iran. According to the results of spatial autocorrelation analysis tests, the distribution of VL was entirely clustered and not random. An important hot spot was located in the northeast of this area. These four regions share borders and are geographically interconnected. Considering that this area is one of the areas of Arasbaran forests and many people are engaged in agriculture and horticulture protecting their livestock and gardens by keeping dogs (the main reservoirs of the disease), they are more likely to develop the incidence of the disease than other areas. The main reservoirs of VL in Iran are dogs and Canidae, including jackals, foxes and wolves, and their abundance in the Arasbaran region is very high and the leishmaniasis parasite is often isolated and reported from the reservoirs in this region \[[@pone.0236414.ref012], [@pone.0236414.ref014], [@pone.0236414.ref015], [@pone.0236414.ref017], [@pone.0236414.ref036], [@pone.0236414.ref046]\].

The presence of definite vectors has caused the northwest region to be at risk for the transmission of the disease because out of six main vectors of VL in Iran, three main vectors are *Ph*. *kandelakii*, *Ph*. *perfiliewi* and *ph*. *tobbi* from the northwest region of Iran \[[@pone.0236414.ref047]--[@pone.0236414.ref051]\]; moreover, the abundance and diversity of sandflies species in this region are important. In a study conducted by Bavia et al. in the Bahia region of Brazil, using the GIS and RS, the high-risk areas of the disease were drawn by maps and the abundance of reservoirs and vectors were determined by matching; it was observed that the contamination of reservoirs and vectors was significantly higher in all areas where VL cases were present \[[@pone.0236414.ref052]\]. Likewise, in another study carried out in some parts of Brazil on the distribution and prediction of VL, using ecological niche model and climatic changes, Paulo Silva identified two new areas that were susceptible to VL located in the northern parts of the endemic areas and provided a map of high-risk areas \[[@pone.0236414.ref053]\].

Based on the results of the Jackknife test, two important seasonal factors, i.e. rainfall and temperature, had an important effect on the abundance of parasites and diseases in the Azerbaijan region. Also, based on existing maps of areas with elevations between 1000 and 1500 meters above sea level, many cases of VL occurred in 1150--1300 m areas. The life cycle of the parasite in the body of the vector, including sandflies and the life cycle of the vectors, is also dependent on two important factors of temperature and humidity \[[@pone.0236414.ref054]\]; similarly, in a study conducted by Moradi-Asl et al. in Ardabil Province \[[@pone.0236414.ref041]\] and a study conducted by Hanafi-Bojd et al. in some regions of Iran \[[@pone.0236414.ref055]\], the effects of these two factors on the distribution of vectors and parasites and the incidence of disease were also emphasized.

The limitation of this study was that just the data from patients enrolled in the three provinces\' health system centers were included in the study. The patients who were diagnosed and treated outside of the three provinces were unavailable. Another limitation was that we extracted data from health record documents and did not deal directly with patients.

Conclusion {#sec013}
==========

Based on the results of this study, the northwestern region of Iran is an important focal point for VL in Iran. Many programs have been undertaken to prevent and control the disease in the endemic areas of northwestern Iran, but most of the cases reported in the country are from the northwest of Iran (Ardabil Province and East Azerbaijan Province). In many counties, the new cases of the disease have been reported from new areas. This indicates the potential for the spread of the disease in these areas. Thus, it is necessary to carry out appropriate studies to investigate vectors in East Azerbaijan Province, evaluate the isolation of parasites from the vectors and determine their strains because the prevention and control of the disease, type of parasite and the type of sandflies transmitting the parasite should be determined in the field.

Supporting information {#sec014}
======================
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7\. We note that Figures \#1, 6 and 7 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1.    You may seek permission from the original copyright holder of Figures \#1, 6 and 7 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (<http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf>) and the following text:

"I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form."

Please upload the completed Content Permission Form or other proof of granted permissions as an \"Other\" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: "Reprinted from \[ref\] under a CC BY license, with permission from \[name of publisher\], original copyright \[original copyright year\]."

2.    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder's requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): <http://viewer.nationalmap.gov/viewer/>

The Gateway to Astronaut Photography of Earth (public domain): <http://eol.jsc.nasa.gov/sseop/clickmap/>

Maps at the CIA (public domain): <https://www.cia.gov/library/publications/the-world-factbook/index.html> and <https://www.cia.gov/library/publications/cia-maps-publications/index.html>

NASA Earth Observatory (public domain): <http://earthobservatory.nasa.gov/>

Landsat: <http://landsat.visibleearth.nasa.gov/>

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <http://eros.usgs.gov/#>

Natural Earth (public domain): <http://www.naturalearthdata.com/>

8\. Please include a copy of Table 2 which you refer to in your text on page 6 and Table 1 and 3 which you refer to in your text on page 7.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dear Authors

Please consider the following comments:

1- Please یouble-check the spelling of the words in all manuscript. For example in title please change leishmaniosis to leishmaniasis.

2- The article needs to be edited in English by a native.

3- Please define in methodology how did you calculated the incidence of VL?

4- Please explain more about the method of analysis for Moran\'s Index and General G analysis. Did you used the points of disease or considered the counties as the analysis units.

5- Please cite a relevant reference for MaxEnt model.

6- The reference 24 cited in line 104 seems to be irrelevant to the analysis.

7- Fig 5 for the result of spatial auto-correlation should be changed with a map resulted from this analysis.

8- In all maps please use \"Urmia Lake\"

9- Table 1 was not included in the reviewed file.

10- Please discuss more about the role of weather and environmental variables on the habitat suitability for life cycle of VL.

Reviewer \#2: This study analyzes the spatial patterns of visceral leishmaniasis in three provinces (Ardabil, East Azerbaijan and West Azerbaijan) in northwestern Iran from 2009 to 2017, as well as its relationship with environmental and geographical factors. The manuscript has a relevant theme, but needs an important review/organization in its content and writing.

-I suggest a comprehensive review of the English written in the manuscript (typographical / grammatical errors and scientific writing);

-Please describe clearly and comprehensively the main problem/object addressed in the manuscript;

-The introduction does not provide an entirely relevant description of the proposal and significance of the study. The problem is not significantly and concisely stated in the text;

-The methods needs to include some additional methodological details in the text (e.g., how morbidity data was extracted or made available; case definition; more information from the surveillance system responsible for the data, etc.), as well as a comprehensive and detailed description of all analyzes presented in the results;

-Overall, the results are not clearly presented and the interpretations and conclusions are not supported and justified by the results, but rather general statements. The limitations of this study are not presented in the text (e.g., coverage and quality of secondary data);

-The titles of figures and tables are not provided in the manuscript, and the tables were not included in the main file.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236414.r002

Author response to Decision Letter 0

13 May 2020

Dear editor of the Plos One

1\) Thank you for your reply. I noted that our ethics committee waived the need for informed consent from the patients and the patients provided consent for the records to be used in this research.

2.) Yes, the Supporting Information files named "GIS Data of VL.xlsx" and "VL Data.xls," along with the data located in our manuscript, constitute the minimal data set required to replicate the conclusions in our study.

3.) Yes, "All relevant data are within the manuscript and its Supporting Information files."

My dear editor,

Thank you very much for that patiently and carefully to your comments and we will guide you. I hope I have answered your questions correctly. We worked hard on this study and took the time. This study was conducted in a very important area of endemic disease and with this study, high-risk areas are easily identified for VL disease control and prevention programs.

Best regards

1\) Thank you once again for your attention to our queries. You have stated that \"This data not including the patients characters (name or address).\" but it is unclear whether while reviewing patients' hospital and health records any of the authors had accessed to potentially identifiable information or whether the authors have only accessed fully anonymized records. Could you please clarify this? Please also state in your ethics statement whether the ethics committee waived the need for consent from the patients or whether you obtained informed consent from the patients for their medical records to be used in research/this study.

We after receiving the ethics code of the ethics committee of Ardabil University of Medical Sciences We used the database of health centers. This data includes patients who have been previously treated. We used demographic characteristics of patients and place of residence to study. The decision of the ethics committee will also be sent to the appendix.

2\) Thank you for your additional data sharing information. If you would like to provide an Excel file containing your data, please upload your minimal anonymized data set to your PLOS ONE submission as a Supporting Information file.

Ok, we\'re sending two Excel files that include:

A. File the number of patients in the study area.

B. The incidence of VL files to different locations for GIS software is used.

My dear Anita Estes ,

PONE-D-19-35837R1

Spatial Autocorrelation and Epidemiological Survey of Visceral Leishmaniasis in an endemic area of Azerbaijan Region, Northwest of Iran

Thank you for better comments.

1\) Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate \"Supporting Information\" files. ( Ok , was done.)

2\) Thank you for removing the funding-related text from the Acknowledgments Section of your manuscript. Please let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"Ardabil University of Medical Sciences\"

(This study was funded Ardabil University of Medical Sciences)

3\) Please amend your authorship list in your manuscript file to include all authors. (The names of the authors were checked and there was no problem).

4\) We note that with regard to the copyright of Figures 1, 6, and 7, you wrote: \"I dragged figures 1, 6 and 7 with the Arcmap GIS 10.4.1 software and uploaded the original file of GIS.\" (Sorry, it was a writing error. They were proper originally by GIS and we uploaded the GIS files . We did not dragged these figures from anywhere).

5\) Please confirm whether the data uploaded as Supporting Information files constitutes the minimal data set, defined as the data set used to reach the conclusions drawn in the manuscript with related metadata and methods, and any additional data required to replicate the reported study findings in their entirety (<https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition>). This may include: a.) The values behind the means, standard deviations and other measures reported; b.) The values used to build graphs; c.) The points extracted from images for analysis. (No, According to ethical approval, patient information is confidential and we can\'t share).

6\) If there are ethical or legal restrictions to sharing third-party data used in your study, and the data included as Supporting Information files in your submission does not meet the requirements in the minimal data set definition above, please provide the following: a.) A description of the data set and the third-party source; b.) If applicable, verification of permission to use the data set; and c.) All necessary contact information others would need to apply to gain access to the data. Please note that it is not acceptable for an author to be the sole named individual responsible for ensuring data access. You can find more information on PLOS ONE's policies regarding acceptable restrictions and third-party data via the following link: <https://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-access-restrictions>. ( Yes, Based on patient information, we cannot share data.).

Thank you

Dr.Eslam Moradi-Asl

My dear editor and reviewers ,

I\'m so sorry. We\'re in control of corona virus that\'s why it\'s late.

We tried to respond to all comments individually.We answered every question or comment in front of you.The English were Native.All shapes and maps were edited.We created all the maps ourselves with the Arcmap GIS 10.4.1 software.

We wish you all health and good time.

PONE-D-19-35837

Spatial Autocorrelation and Epidemiological Survey of Visceral Leishmaniosis in an endemic area of Azerbaijan Region, Northwest of Iran

PLOS ONE

Additional Editor Comments (if provided):

-Improve titles in Results section to be more descriptive. ( Ok , Edited )

\- Include legends to figures. (Ok , Edited )

\- Check figures axes titles. For example, Y axis in figure 4 is labeled 'Vl' instead of 'VL'. Ok , Edited )

-. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section. Ok, the limitations of the study were discussed at the end.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

(Ok, was done )

2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. (Ok, was done )

3\. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section. (Ok, was done )

4\. During your revisions, please note that a simple title correction is required to ensure correct spelling. The title should read: \"Spatial Autocorrelation and Epidemiological Survey of Visceral Leishmaniasis in an endemic area of Azerbaijan Region, Northwest of Iran\". Please ensure this is updated in the manuscript file and the online submission information. (Ok, was done )

5\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

\"This work was supported by the Ardabil University of Medical Sciences (Project numbers 92218).\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"Ardabil University of Medical Sciences \" (Ok, was done )

6\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

The Excel and GIS format of the data and maps is sent to the attachment.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7\. We note that Figures \#1, 6 and 7 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1\. You may seek permission from the original copyright holder of Figures \#1, 6 and 7 to publish the content specifically under the CC BY 4.0 license.

\*\*\* I dragged figures 1, 6 and 7 with the Arcmap GIS 10.4.1 software and uploaded the original file of GIS.\*\*\*\*\*

We recommend that you contact the original copyright holder with the Content Permission Form (<http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf>) and the following text:

"I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form."

Please upload the completed Content Permission Form or other proof of granted permissions as an \"Other\" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: "Reprinted from \[ref\] under a CC BY license, with permission from \[name of publisher\], original copyright \[original copyright year\]."

2\. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder's requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): <http://viewer.nationalmap.gov/viewer/>

The Gateway to Astronaut Photography of Earth (public domain): <http://eol.jsc.nasa.gov/sseop/clickmap/>

Maps at the CIA (public domain): <https://www.cia.gov/library/publications/the-world-factbook/index.html> and <https://www.cia.gov/library/publications/cia-maps-publications/index.html>

NASA Earth Observatory (public domain): <http://earthobservatory.nasa.gov/>

Landsat: <http://landsat.visibleearth.nasa.gov/>

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <http://eros.usgs.gov/#>

Natural Earth (public domain): <http://www.naturalearthdata.com/>

8\. Please include a copy of Table 2 which you refer to in your text on page 6 and Table 1 and 3 which you refer to in your text on page 7.

Ok , was done

Reviewer \#1: Dear Authors

Please consider the following comments:

1- Please double-check the spelling of the words in all manuscript. For example in title please change leishmaniosis to leishmaniasis. ( Ok , it is done)

2- The article needs to be edited in English by a native.( It was native).

3- Please define in methodology how did you calculated the incidence of VL?

R: (The effect of variables, such as age, sex and location, on the prevalence (No. of VL cases/population size \* 100000) of the disease was evaluated using SPSS version 23(Chicago, IL, USA)

4- Please explain more about the method of analysis for Moran\'s Index and General G analysis. Did you used the points of disease or considered the counties as the analysis units.

R: (Moran\'s I Index and General G value were measured, and both the score and p-values (p \< 0.05) were calculated and used to evaluate the significance of the index (27). Moran's I is a commonly used indicator of spatial autocorrelation. In this study, global Moran's I was used as the first measure of spatial autocorrelation. Its values range from−1 to 1. The value "1" means perfect positive spatial autocorrelation (high values or low values cluster together), while "−1" suggests perfect negative spatial auto-correlation (a checkerboard pattern), and "0" implies perfect spatial randomness (28, 29) . The High/Low Clustering (General G) tool measures how concentrated the high or low values are for a given study area. This tool calculates the High/Low General G value (observed & expected) & the associated Z score & p-value for a given input feature class(30).)

5- Please cite a relevant reference for MaxEnt model.( Ok , Reference 31 , Young N, Carter L, Evangelista P. A MaxEnt model v3. 3.3 e tutorial (ArcGIS v10). Fort Collins, Colorado. 2011.)

6- The reference 24 cited in line 104 seems to be irrelevant to the analysis.( Reference edited )

7- Fig 5 for the result of spatial auto-correlation should be changed with a map resulted from this analysis. (Figure 5 is the software output and is intended to illustrate the relationship).

8- In all maps please use \"Urmia Lake\" , ( Ok , Was done).

9- Table 1 was not included in the reviewed file. ( This is for Editor)

10- Please discuss more about the role of weather and environmental variables on the habitat suitability for life cycle of VL.

Reviewer \#2: This study analyzes the spatial patterns of visceral leishmaniasis in three provinces (Ardabil, East Azerbaijan and West Azerbaijan) in northwestern Iran from 2009 to 2017, as well as its relationship with environmental and geographical factors. The manuscript has a relevant theme, but needs an important review/organization in its content and writing. ( Ok , The manuscript was edited native )

-I suggest a comprehensive review of the English written in the manuscript (typographical / grammatical errors and scientific writing); Ok , The manuscript was edited native

-Please describe clearly and comprehensively the main problem/object addressed in the manuscript; The introduction was edited

-The introduction does not provide an entirely relevant description of the proposal and significance of the study. The problem is not significantly and concisely stated in the text; ( Ok , Accordingly, this study aimed to investigate the geographical distribution of VL in three provinces of Ardabil, East Azerbaijan and West Azerbaijan (northwestern Iran) and determine the high-risk areas of the disease in the provinces and its relation with environmental and geographical factors. Another objective of the study was to determine the environmental suitability for VL in northwestern Iran for prevention and control of diseases.)

-The methods needs to include some additional methodological details in the text (e.g., how morbidity data was extracted or made available; case definition; more information from the surveillance system responsible for the data, etc.), as well as a comprehensive and detailed description of all analyzes presented in the results; Ok, was edited ((In this retrospective cross-sectional study, the Data on VL cases were collected from Ardabil, East Azerbaijan and West Azerbaijan Provinces health centers during the last 9yr from January 2009 to the end of December 2017. The number of patients with Direct Agglutination Test (DAT) positive serologic tests was more than 1:3200 cases with medical records, diagnosed by physicians and treated in different parts of the province. By referring to health centers in different counties and reviewing patients' hospital and health records, demographic characteristics, including age, sex, place of residence, month and year of the disease as well as the results of the DAT test were collected. Then, the data collected were compared with the general statistics in the offices of the vice-chancellor for the health of the provinces of East Azerbaijan, West Azerbaijan, and Ardabil, and the results of the comparison were recorded. The collected data were stored in an ArcMap environment based on the patients' addresses.))

-Overall, the results are not clearly presented and the interpretations and conclusions are not supported and justified by the results, but rather general statements. The limitations of this study are not presented in the text (e.g., coverage and quality of secondary data); Once again the whole article was edited according to your comments and it was native.

-The titles of figures and tables are not provided in the manuscript, and the tables were not included in the main file.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0236414.r003

Decision Letter 1

Schriefer

Albert

Academic Editor

© 2020 Albert Schriefer

2020

Albert Schriefer

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

24 Jun 2020

PONE-D-19-35837R1

Spatial Autocorrelation and Epidemiological Survey of Visceral Leishmaniasis in an endemic area of Azerbaijan Region, Northwest of Iran

PLOS ONE

Dear Dr. Moradi-Asl,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

More specifically, please fully incorporate the two remaining comments made by reviewer 1 in the revised version of the manuscript (i.e. R1). Also, address the few editorial comments made in the ´Aditional Editor Comments´ space right after the signature field at the bottom of this message.

Please submit your revised manuscript by Aug 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Albert Schriefer, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Introduction, line 43. I suggest adjusting ´there is a high correlation between the life cycle of the VL disease and the environmental factors involved in it \...´ to  ´there is a high correlation between the occurrence of the VL disease and the environmental factors involved in it \...´.Methods, lines 111-114. Please, refer to table 1 here: ´A total of 19 climate variables were downloaded from the 111 Worldclime website ([www.worldclime.com](http://www.worldclime.com)) with a resolution of 30 sec (�1 sq.km) and were used 112 along with an elevation variable at the same resolution to evaluate and determine the appropriate 113 ecological niches (Table 1)´.Tables 2 and 3. Please, invert the tables. Titles are correct, but the corresponding tables have been inverted.Table ´The results of T-test and Kruskal --walls test for incidence of VL \...´. In the cell ´\<1000 -1150\>´, I suggest substituting this label with either ´Lower than 1000 and higher than 1150´, or ´\<1000 and \>1150´.Results, lines 175-176. Please, further clarify the sentence ´ the results of the investigation of the impact of all variables together on the model were precipitation seasonality (35.40%) and mean diurnal range (21.60%)´. As currently written it is confusing.Results, line 176. Please, correct ´(Table 1and 3)´ to (Table 1)´.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dear Authors

Thank you for addressing most of the comments. Still I think two comments are not addressed:

1- Did you used the points of VL disease for Moran\'s analysis or considered the counties as the analysis units?

2- Fig 5 for the result of spatial auto-correlation should be replaced with a map resulted from this analysis. You can ask Arcmap to plot the map i this analysis.

Good luck

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

1 Jul 2020

My dear editor,

Thanks for you and Reviewers and good time.

Additional Editor Comments (if provided):

1\. Introduction, line 43. I suggest adjusting ´there is a high correlation between the life cycle of the VL disease and the environmental factors involved in it \...´ to ´there is a high correlation between the occurrence of the VL disease and the environmental factors involved in it \...´. Ok, was done.

2\. Methods, lines 111-114. Please, refer to table 1 here: ´A total of 19 climate variables were downloaded from the 111 Worldclime website ([www.worldclime.com](http://www.worldclime.com)) with a resolution of 30 sec (�1 sq.km) and were used 112 along with an elevation variable at the same resolution to evaluate and determine the appropriate 113 ecological niches (Table 1)´. Ok, was done.

3\. Tables 2 and 3. Please, invert the tables. Titles are correct, but the corresponding tables have been inverted. Ok, was done.

4\. Table ´The results of T-test and Kruskal --walls test for incidence of VL \...´. In the cell ´\<1000 -1150\>´, I suggest substituting this label with either ´Lower than 1000 and higher than 1150´, or ´\<1000 and \>1150´. Ok, was done.

5\. Results, lines 175-176. Please, further clarify the sentence ´ the results of the investigation of the impact of all variables together on the model were precipitation seasonality (35.40%) and mean diurnal range (21.60%)´. As currently written it is confusing. Ok, was done and edited (Once, the impact of each variable on the model was evaluated separately (Fig 8). In addition, the impact of all variables together on the model were precipitated again. The model showed that two factors; seasonality (35.40%) and mean diurnal range (21.60%) had the greatest impact on the occurrence of the disease)

6\. Results, line 176. Please, correct ´(Table 1and 3)´ to (Table 1)´. Ok, was done.

Reviewer \#1: Dear Authors

Thank you for addressing most of the comments. Still I think two comments are not addressed:

1- Did you used the points of VL disease for Moran\'s analysis or considered the counties as the analysis units? We used the points of VL disease for Moran\'s analysis.

2- Fig 5 for the result of spatial auto-correlation should be replaced with a map resulted from this analysis. You can ask Arcmap to plot the map i this analysis. To determine the autocorrelation, the Moran and G index have been used, and the Arcmap software output is in the form of a graph, not a map.

Best regards

Dr.Eslam Moradi-Asl

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Decision Letter 2

Schriefer

Albert

Academic Editor

© 2020 Albert Schriefer

2020

Albert Schriefer

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8 Jul 2020

Spatial Autocorrelation and Epidemiological Survey of Visceral Leishmaniasis in an endemic area of Azerbaijan Region, Northwest of Iran

PONE-D-19-35837R2

Dear Dr. Moradi-Asl,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Albert Schriefer, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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Spatial autocorrelation and epidemiological survey of visceral leishmaniasis in an endemic area of Azerbaijan region, the northwest of Iran

Dear Dr. Moradi-Asl:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Albert Schriefer

Academic Editor

PLOS ONE
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